NEWS
< back to news list

NanoGroup S.A. expands its operations to a new research area and will develop innovative products in targeted oncological treatment

NanoGroup S.A. has submitted an application for funding under the COMPETITION FOR ENTREPRENEURS FOR THE IMPLEMENTATION OF RESEARCH IN THE AREA OF DRUG SAFETY, INNOVATIVE THERAPIES AND FUTURE DRUGS COMPETITION NUMBER: 2024/ABM/05/KPO financed by the Medical Research Agency. The Polish biotechnology company is applying for funds for the development of targeted therapies for oncological treatment using conjugates.

The progress in oncology that we are witnessing has meant that today many cancers are no longer referred to as terminal illnesses, but as chronic diseases. New, targeted therapies offer a chance for a complete cure of cancer if detected early, as well as a longer life for patients with advanced or generalized disease. Particular hopes are placed in conjugates. These are innovative delivery systems that consist of a carrier, a targeting agent, and a cytostatic drug.

Research on conjugates is another area that NanoGroup S.A. intends to develop, and the company plans to obtain funds for this purpose, among others, from the Medical Research Agency. These funds will allow for financing research and development works until the commencement of preclinical studies on animals.

The development of conjugate technology is one of the milestones included in the NanoGroup S.A. strategy for 2023-2025. The company has already made preparations for its implementation – based on its own analytical model, five active particles out of 250 with the greatest therapeutic and market potential were selected.

The researchers now face further work that is to lead to the creation of new functional combinations of selected cytostatic drugs with a carrier and a targeting factor. Dextran, a water-soluble biocompatible polysaccharide with a three-dimensional structure and a large loading capacity for drugs and targeting factors, will be used as the carrier. In implementing this project, the company uses the experience and patents already gained within the capital group.

The project is planned to develop pathways for the synthesis of conjugates, investigate the kinetics of drug release depending on pH, conduct in vitro studies of conjugate binding on cancer cell lines, perform comparative studies of conjugate cytotoxicity in relation to the effect of the free drug, and conduct preliminary studies in mice.

The competition for entrepreneurs to carry out research in the area of drug safety, innovative therapies and medicines of the future is organized as part of the National Plan for Reconstruction and Increased Resilience Component D Efficiency, availability and quality of the healthcare system. The main goal of the initiative is to increase the efficiency and quality of the healthcare system by supporting the Polish research and development potential in the biomedical area. A total amount of PLN 350 million has been earmarked for the implementation of the tasks, with the minimum value of funding for one project being PLN 2 million and the maximum being PLN 12 million.

Copyright © NanoGroup 2024

Prof. Tomasz Ciach

Founder, Member of the Management Board of NANOGROUP S.A.

Nanotechnology expert. Professor at the Faculty of Chemical and Processing Engineering, Warsaw University of Technology, head of the Biotechnology and Bioprocessing Division. Author of two technologies that are already in production stage, 12 granted patents and over 50 publications. Founder of BioMedLab research group, consultant in numerous companies (AstraZeneca, Procter and Gamble, Reckit, Adamed, Balton, Galmed). Work on various aspects of Biomedical Engineering, mostly on biomedical nanotechnology, active coatings for medical implants, nanoparticles for cancer treatment, biodegradable and nonbiodegradable implants, bone and vascular prosthesis. He gives rare, but already brilliant example of how brave ideas become socially and financially valuable.

Piotr Mierzejewski

Vice President of the Management Board of NANOGROUP S.A.

Clinical pharmacology specialist, former advisor to the Minister of Health on drug policy. He negotiated Poland’s accession to the EU in the field of pharmacy, responsible for the implementation of EU directives in the field of pharmacy into the Polish legal system. Co-founder of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. Owner of a consulting company cooperating with international pharmaceutical companies in the field of introducing new technologies to the Polish market.

Przemysław Mazurek

President of the Management Board of NANOGROUP S.A.

Associated with the health market since 2004. As Managing Director, he restructured and developed the most dynamically operating Medical Center in the Podkarpacie region, creating and setting new standards of customer service quality on the market. Co-creator of the first solution in Poland for online registration of medical appointments. Co-founder of the first and only Infertility Treatment Clinic (MEDICOR) in Podkarpacie, which he headed as the President until 2009. He was responsible for the development of health insurance in the PZU Group. As Vice President of PZU Pomoc S.A. created the largest medical TPA in Poland to handle health insurance. Co-founder of the first drug insurance in Poland. Since 2015, he has been active in the field of Wealth Management and advises on management and finance. A graduate of International Economic and Political Relations as well as Management and Marketing at the Warsaw School of Economics.

Przemysław Mazurek

President of the Management Board of NANOGROUP S.A.

Associated with the health market since 2004. As Managing Director, he restructured and developed the most dynamically operating Medical Center in the Podkarpacie region, creating and setting new standards of customer service quality on the market. Co-creator of the first solution in Poland for online registration of medical appointments. Co-founder of the first and only Infertility Treatment Clinic (MEDICOR) in Podkarpacie, which he headed as the President until 2009. He was responsible for the development of health insurance in the PZU Group. As Vice President of PZU Pomoc S.A. created the largest medical TPA in Poland to handle health insurance. Co-founder of the first drug insurance in Poland. Since 2015, he has been active in the field of Wealth Management and advises on management and finance. A graduate of International Economic and Political Relations as well as Management and Marketing at the Warsaw School of Economics.